Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.

Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G

Open source

DOI: 10.1016/s0140-6736(22)00466-4
Published: 2022 May 28
Container: Lancet (London, England)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-22-00466-4,
  title = {Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.},
  author = {Ferrante M and Panaccione R and Baert F and Bossuyt P and Colombel JF and Danese S and Dubinsky M and Feagan BG and Hisamatsu T and Lim A and Lindsay JO and Loftus EV Jr and Panés J and Peyrin-Biroulet L and Ran Z and Rubin DT and Sandborn WJ and Schreiber S and Neimark E and Song A and Kligys K and Pang Y and Pivorunas V and Berg S and Duan WR and Huang B and Kalabic J and Liao X and Robinson A and Wallace K and D'Haens G},
  year = {2022},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(22)00466-4},
  url = {https://doi.org/10.1016/s0140-6736(22)00466-4}
}

RIS

TY  - JOUR
TI  - Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
AU  - Ferrante M
AU  - Panaccione R
AU  - Baert F
AU  - Bossuyt P
AU  - Colombel JF
AU  - Danese S
AU  - Dubinsky M
AU  - Feagan BG
AU  - Hisamatsu T
AU  - Lim A
AU  - Lindsay JO
AU  - Loftus EV Jr
AU  - Panés J
AU  - Peyrin-Biroulet L
AU  - Ran Z
AU  - Rubin DT
AU  - Sandborn WJ
AU  - Schreiber S
AU  - Neimark E
AU  - Song A
AU  - Kligys K
AU  - Pang Y
AU  - Pivorunas V
AU  - Berg S
AU  - Duan WR
AU  - Huang B
AU  - Kalabic J
AU  - Liao X
AU  - Robinson A
AU  - Wallace K
AU  - D'Haens G
PY  - 2022
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(22)00466-4
UR  - https://doi.org/10.1016/s0140-6736(22)00466-4
ER  -

APA

M, F., R, P., F, B., P, B., JF, C., S, D., M, D., BG, F., T, H., A, L., JO, L., Jr, L. E., J, P., L, P., Z, R., DT, R., WJ, S., S, S., E, N., A, S., K, K., Y, P., V, P., S, B., WR, D., B, H., J, K., X, L., A, R., K, W., & G, D. (2022). Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(22)00466-4

Source records

pubmed · retrieved 2026-09-25T20:47:28.339Z
europe-pmc · retrieved 2026-09-25T20:47:28.350Z
hal · retrieved 2026-09-25T20:47:28.385Z